Related Experiment Video
Updated: Aug 5, 2026
08:23
Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
Repurposing Tyrosine Kinase Inhibitors for Sickle Cell Disease: Focus on Band 3 Phosphorylation
Raj Gupta1, Neha Mishra2, Manisha Madkaikar1
1Indian Council of Medical Research, National Institute for Research on Blood and Immune Disorders (Formally NIIH), Mumbai 400012, MH, India.
Biomedicines
|July 28, 2026
Summary
Sickle cell disease involves red blood cell damage triggered by hemoglobin S. Targeting specific tyrosine kinases may restore red blood cell function and reduce disease complications.
Area of Science:
- Biochemistry
- Hematology
- Molecular Biology
Background:
- Sickle cell disease (SCD) is a genetic disorder caused by hemoglobin S (HbS), leading to red blood cell (RBC) dysfunction.
- HbS polymerization under deoxygenation induces oxidative stress and Band 3 protein aggregation in RBCs.
- Band 3 phosphorylation by tyrosine kinases alters RBC membrane integrity and function.
Purpose of the Study:
- To review the regulation of Band 3 protein by spleen tyrosine kinase (SYK) and Src family kinases in SCD.
- To explore the therapeutic potential of tyrosine kinase inhibitors (TKIs) in managing SCD.
Main Methods:
- Review of literature on tyrosine kinase regulation of Band 3 in sickle cell disease.
- Analysis of kinase structural features (SH2 domains) for substrate recognition.
- Evaluation of in vitro data on TKI efficacy in SCD models.
Main Results:
- Tyrosine kinases, particularly SYK and Src family kinases, sequentially phosphorylate Band 3, impacting RBC mechanics.
- Inhibiting these kinases with TKIs reduces Band 3 phosphorylation, improving RBC deformability.
- TKIs demonstrate potential in vitro to decrease hemolysis and vaso-occlusive events in SCD.
Conclusions:
- Targeting SYK and Src family kinases offers a promising therapeutic strategy for SCD.
- TKIs can restore RBC function by modulating Band 3 phosphorylation, potentially alleviating SCD pathology.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...